Archive for the ‘Gene Therapy Research’ Category

Copy number regulation by cop genes
For more information, log on to- shomusbiology.weebly.com Download the study materials here- shomusbiology.weebly.com Plasmids used in genetic engineering are called vectors. Plasmids serve as important tools in genetics and biotechnology labs, where they are commonly used to multiply (make many copies of) or express particular genes.[4] Many plasmids are commercially available for such uses. The gene to be replicated is inserted into copies of a plasmid containing genes that make cells resistant to particular antibiotics and a multiple cloning site (MCS, or polylinker), which is a short region containing several commonly used restriction sites allowing the easy insertion of DNA fragments at this location. Next, the plasmids are inserted into bacteria by a process called transformation. Then, the bacteria are exposed to the particular antibiotics. Only bacteria that take up copies of the plasmid survive, since the plasmid makes them resistant. In particular, the protecting genes are expressed (used to make a protein) and the expressed protein breaks down the antibiotics. In this way, the antibiotics act as a filter to select only the modified bacteria. Now these bacteria can be grown in large amounts, harvested, and lysed (often using the alkaline lysis method) to isolate the plasmid of interest. Another major use of plasmids is to make large amounts of proteins. In this case, researchers grow bacteria containing a plasmid harboring the gene of interest. Just as the ...

By: Suman Bhattacharjee

Read the rest here:
Copy number regulation by cop genes - Video

Stimulus
Made up of appropriated pharmaceutical television commercials, "Stimulus" plays off of the double meaning of economic and bodily/chemical stimuli. Using a series of precisely edited snippets, the piece quickly builds to a stuttering, hysterical/historical tangle of language, image, and the molecular body. Amongst other things, it is about looking and consuming, gender politics, biopower, and capital. The length of the piece is a restrained one minute, a tightly crafted piece to match a traditional 60 second advertising spot. "Stimulus" follows a repetition/break structure, a classical advertising (and noted storytelling/folktale) technique in which expectations are created/repeated and then thwarted in the final moment. It uses abrasive, repetitive editing along with humor and breaks to seduce the viewer into its rhythm. Two images are arranged one on top of the other, and the screen is oriented vertically, unlike traditional film and video (and more along the lines of increasing tendencies for video to be shot vertically on smartphones). In the installation, the screens are then multiplied, in itself a repetition of the image and suggestive of the repetitive nature of consumption and excretion, as well as defining a human, figurative space. The original clips are thus twice rotated in order to be read by the viewer, a kind of double-gymnastics. My video practice draws inspiration in particular from the work of Sturtevant and Gretchen Bender, amongst others who use ...

By: Jeff Ostergren

Follow this link:
Stimulus - Video

IRBBA Donation Heifer 2013 - Buffaole #39;s Ms Vincent 225Z
The IRBBA Scholarship Foundation is proud to introduce Buffaloe #39;s Ms Vincent 225Z as the 2013 Donation Heifer. Bred and contributed by Buffaloe Cattle Company, the heifer will be raffled at the "Divas in Red" sale during the 2013 IRBBA Annual Meeting, April 27th in College Station, Texas. The tradition of a donation heifer to support the Scholarship Foundation was initiated in 2012 with the first heifer contributed by Cox Excalibur Brangus, selling to Buffaloe Cattle Company. This year a limited number of tickets will be sold for a chance to own this exciting young female. Only 50 tickets at $100 each will be offered from now until sale date. Participating donors will have one chance to per ticket to win this elite Red Brangus heifer in the raffle. Buffaloe #39;s Ms Vincent 225Z has a pedigree that includes a "who #39;s who" in Red Brangus genetics. She is sired by Buffaloe #39;s Vincent 07X, a Sureway #39;s Rocky Street 227N son. Rocky Street was the 2007 and 2008 Red Brangus Show Sire of the Year. Vincent #39;s dam, BCC Chief #39;s Squaw 7P was the Grand Champion female in the 2006 Brangus Futurity and Reserve Grand Champion in the 2006 San Antonio Livestock Exposition. Vincent and 225Z boast solid Sureways and CX breeding in their pedigree. Vincent has four grand champions in his three generation maternal pedigree plus Rocky Street. The dam of Buffaloe #39;s Ms Vincent 225Z is a daughter of -C- Mesa and boasts 5 Champions in her pedigree as well as posting a top 5% ranking for IMF. 225Z is a ...

By: idealvideopro

More:
IRBBA Donation Heifer 2013 - Buffaole's Ms Vincent 225Z - Video

OBG
Oklahoma Bovine Genetics Sale Preview Visit obgcattle.com for sale details.

By: Tawnia Jo Misemer

Read the rest here:
OBG - Video

LOOK BEHIND YOU! (The Hidden)
#9658; #9658; #9658; Enjoy the video? Subscribe! bit.ly #9668; #9668; #9668; Download Here: http://www.hidden-source.com What is The Hidden? "In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all records and traces of the experiments ...

By: SeaNanners

Read the rest here:
LOOK BEHIND YOU! (The Hidden) - Video

Is Breast Cancer Hereditary Video
is-genetics-a-risk-factor-for-breast-cancer-with-jason-cord-md

By: AHJDietNWeightLoss

Go here to read the rest:
Is Breast Cancer Hereditary Video - Video

Sex Advice for Nice Guys who have intellectual potential part 1
Part 2 here: youtu.be -------------------------------------------------------------------------- The real dictionary definition of a NiceGuy? NICE GUY: -NiceGuys are only allowed to be "Asexual", like a unick! -NiceGuys are not allowed to have a relationship with someone they are in-love with or anyone usually! -NiceGuys have to always do favors and never is allowed to seek or receive reward! -NiceGuys are like Circumcised-Servant-Products to be ordered around! (I #39;m pretty sure women only call you for favors) -It is immoral for a NiceGuys to say "NO"! -It is forbidden for a NiceGuy to request his sexual romance needs! -------------------------------------------------------------------------- Stop saying "YES" and being nice to woman to who don #39;t give a sh*t about your life!! You can always meet new people and make new friends who won #39;t abuse you!, or else leave your new abusive friends and meet other ones!! Who cares if you have been doing favors for your Female Friend for over 10 years!! F*CK HER and don #39;t hang around as much even if she puts a guilt trip on you! She ain #39;t sucking your d*ck nor giving you her superficial p*ssy, so FORGET HER if she is not being the type of friend you need to be happy! You shouldn #39;t tolerate fake companionship! Look for real partnership!! Stop being a NiceGuy, your better smarter than that! Women were never designed to benefit NiceGuys! AND NEVER WILL BE Be mentally ill by going against your personality and nature!! It #39;s the ONLY way ...

By: Proud Hypocrite

Read more:
Sex Advice for Nice Guys who have intellectual potential part 1 - Video

Update!
Hey! It #39;s been 2 years since I uploaded a video so that #39;s cool. I hope everyone is fantastic and I apologize for my awkwardness and if you can hear the dishwasher running in the background! I also got a new computer where you can #39;t hear the fan so thats pretty awesome too. Also I #39;m not very good at video making skills and how not to look 12 years old. But I feel like the latter is due to genetics and I don #39;t think I can really do anything about that 🙁

By: Canitoch

Follow this link:
Update! - Video

LONDON - A genetic variant commonly found in Chinese people may help explain why some got seriously ill with swine flu, a discovery scientists say could help pinpoint why flu viruses hit some populations particularly hard and change how they are treated.

Less than one per cent of Caucasians are thought to have the gene alteration, which has previously been linked to severe influenza. Yet about 25 per cent of Chinese people have the gene variant, which is also common in Japanese and Korean people.

British and Chinese researchers analyzed 83 patients admitted to a Beijing hospital during the 2009-2010 swine flu pandemic. Of those with serious complications like pneumonia, respiratory or kidney failure, 69 per cent had the genetic alteration. Among patients with mild illness, only 25 per cent did.

"It doesn't mean you should panic if you have this gene variant," said Andrew McMichael, director of the Weatherall Institute of Molecular Medicine at Oxford University, one of the study's authors. "Most people who have it won't run into any trouble at all."

He suggested people with this genetic predisposition to severe flu should be treated earlier and more aggressively than others.

McMichael estimated that people with the genetic variant were five to six times more likely to get severely ill once they're infected. The gene alteration doesn't make people more likely to catch the flu, since that depends on other factors like environmental exposure and previous immunity.

McMichael said the gene variant might give people the same susceptibility to get severely ill from other ailments including dengue, SARS and other flus. But it could also provide them with better immunity if they recover.

The research was published online Tuesday in the journal Nature Communications.

Some experts said it was an intriguing finding that shows a patient's response to a virus may determine how sick they will become.

"The bug in someone who gets severely ill is not any different than the one that infects someone who has mild illness," said Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, who did not participate in the study. "It's the host that does all the damage to themselves."

Read the rest here:
Genetics may explain why some Chinese got severe swine flu, could change flu treatments

Seattle Genetics, Inc. (SGEN) recently presented interim results from a phase I study which is evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (:PDA).

Seattle Genetics is developing ASG-5ME, an antibody-drug conjugate (ADC) which targets the SLC44A4 antigen, for the treatment of solid tumors. The candidate is being developed in collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. (ALPMY).

The trial is being conducted to evaluate the safety and activity along with identifying the maximum tolerated dose (MTD) of ASG-5ME in patients suffering from metastatic PDA. Approximately 35 patients with metastatic PDA and a median age of 63 were administered doses ranging from 0.3 milligrams per kilogram (mg/kg) to 1.5 mg/kg administered weekly for three of every four weeks. Data from the study, apart from providing preliminary evidence for antitumor activity, revealed that the candidate was well tolerated.

We note that Seattle Genetics is also evaluating ASG-5ME in the prostate and gastric cancer indications. Seattle Genetics focuses on the development and commercialization of monoclonal antibody-based therapies for cancer.

We remind investors that Seattle Genetics leading drug, Adcetris, is currently approved in the US for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (:ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients, who are not suitable for ASCT and the treatment of sALCL in treatment-experienced patients. Adcetris is approved in the EU as well.

Seattle Genetics carries a Zacks Rank #3 (Hold). Pharma stocks, which currently appear to be more attractive include Valeant Pharmaceuticals (VRX) and Salix Pharmaceuticals (SLXP). Both companies carry a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on ALPMY

Read the Full Research Report on SGEN

Zacks Investment Research

Here is the original post:
Data From SGEN on Cancer Candidate

LONDON (AP) -- A genetic variant commonly found in Chinese people may help explain why some got seriously ill with swine flu, a discovery scientists say could help pinpoint why flu viruses hit some populations particularly hard and change how they are treated.

Less than one percent of Caucasians are thought to have the gene alteration, which has previously been linked to severe influenza. Yet about 25 percent of Chinese people have the gene variant, which is also common in Japanese and Korean people.

British and Chinese researchers analyzed 83 patients admitted to a Beijing hospital during the 2009-2010 swine flu pandemic. Of those with serious complications like pneumonia, respiratory or kidney failure, 69 percent had the genetic alteration. Among patients with mild illness, only 25 percent did.

"It doesn't mean you should panic if you have this gene variant," said Andrew McMichael, director of the Weatherall Institute of Molecular Medicine at Oxford University, one of the study's authors. "Most people who have it won't run into any trouble at all."

He suggested people with this genetic predisposition to severe flu should be treated earlier and more aggressively than others.

McMichael estimated that people with the genetic variant were five to six times more likely to get severely ill once they're infected. The gene alteration doesn't make people more likely to catch the flu, since that depends on other factors like environmental exposure and previous immunity.

McMichael said the gene variant might give people the same susceptibility to get severely ill from other ailments including dengue, SARS and other flus. But it could also provide them with better immunity if they recover.

The research was published online Tuesday in the journal Nature Communications.

Some experts said it was an intriguing finding that shows a patient's response to a virus may determine how sick they will become.

"The bug in someone who gets severely ill is not any different than the one that infects someone who has mild illness," said Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, who did not participate in the study. "It's the host that does all the damage to themselves."

Original post:
Genetics may explain severe flu in Chinese people

New Zealands largest red meat genetics company, Focus Genetics has merged its resources with the UKs leading supplier of sheep technologies, providing UK farmers with a wider range of improved sheep genetics.

Innovis chief executive Dewi Jones has just returned from meeting with farmers in New Zealand where he signed a distribution agreement with Focus Genetics (previously Rissington Breedline UK) that will enable the organisation to market rams from one of the biggest sheep gene pools in the world.

Focus Genetics UK General Manager, Bayden Wilson says the collaboration with Innovis will enable them to improve the supply of their genetics to UK breeders and allow them to increase investment in ground-breaking research and development technologies for the benefit of farmers.

"By working with Innovis we can produce better genetic gains from our UK stock and create efficiencies from the ability to share resources, skills, technologies and equipment."

Focus Genetics currently provide around 300 Primera and Highlander rams to UK Farmers annually, from South West England to the Orkney Islands and Ireland.

Innovis has already established a substantial customer base with more than 450 farms using their Aberdale, Aberfield, Abermax and Abertex breeds.

As a result of the collaboration, more than 800 rams will be available through Innovis in 2013.

Mr Wilson will continue to be involved with the UK business working with UK breeders and assisting Innovis to service current farmers and grow the business.

"We already have a significant number of farmers using both Focus and Innovis rams. Collaboration means farmers will be better serviced year round and we expect to significantly increase the sale of both genetics over the coming years."

Innovis chief executive Dewi Jones says he was impressed with what he saw while in New Zealand and believes UK farmers will benefit from the Focus Genetics breeds.

Excerpt from:
UK farmers now have wider choice of NZ sheep genetics

SEATTLE, WA--(Marketwire - Jan 28, 2013) - Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, announced today that Dr. Steven C. Quay, M.D., Ph.D., FCAP, Chairman, CEO and President, will present the Company's products and services at the 15th Annual BIO CEO and Investor Conference at the Waldorf Astoria Hotel in New York City, on Monday, February 11, 2013, at 1:00 pm Eastern Time (10:00 am Pacific Time). Dr. Quay's presentation will be webcast via the Company's website at http://www.atossagenetics.com.

Dr. Quay stated, "The national launch of our ForeCYTE Breast Health Test is an important achievement that positions Atossa for accelerated growth in 2013 and beyond. I look forward to presenting our business model, marketing plan, and additional products and laboratory services to institutional investors at this premier event. I believe the 2013 U.S. rollout of our ForeCYTE and ArgusCYTE Breast Health Test, launch of the FullCYTE Breast Health Test and NextCYTE Breast Health Test, and initiation of clinical trials for our intraductal therapy, represent significant upside potential for investors this year."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission.All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

See the original post here:
Atossa Genetics to Present at the 15th Annual BIO CEO and Investor Conference

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that it will report its fourth quarter and year 2012 financial results on Tuesday, February 12, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Tuesday, February 12, 2013

1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

REPLAY access

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The companys lead program, ADCETRIS, received accelerated approval from the U.S. Food and Drug Administration in August 2011 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional approval from the European Commission in October 2012. Seattle Genetics also has three other clinical-stage antibody-drug conjugate (ADC) programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at http://www.seattlegenetics.com.

Read the rest here:
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2012 Financial Results on ...

AMES, Iowa, Jan. 29, 2013 /PRNewswire/ --NewLink Genetics Corporation (NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The Company intends to use the net proceeds from the offering for general corporate purposes, including regulatory, clinical trial, research and development, general and administrative and manufacturing expenses. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jefferies & Company, Inc. and Stifel Nicolaus Weisel are acting as joint book-running managers in the offering.

The securities described above are being offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com, or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. NewLink's portfolio includes biologic and small-molecule immunotherapy product candidates intended to treat a wide range of oncology indications.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "expect," "intend," "may," "will,""could," "should," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about the Company's expectations with respect to its proposed offering, including its intention to offer and sell shares, its intention to grant the underwriters an option to purchase additional shares and its intended use of proceeds from the offering. Such statements are based on the Company's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as those risks discussed in NewLink's Annual Report on Form 10-K for the year ended December 31, 2011, in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012, and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release represent NewLink's views as of the date of this press release. NewLink anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink's views as of any date subsequent to the date of this press release.

Contact: Gordon Link Chief Financial Officer 515-598-2925 glink@linkp.com

Go here to read the rest:
NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock

SAN DIEGO, Jan. 29, 2013 /PRNewswire/ --Cardium Therapeutics (NYSE MKT: CXM) today announced a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The Company's presentation, "Optimizing Phase III Trial Design for Generx (Ad5FGF-4)" by Cardium's Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D. outlined the current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and discussed the lessons learned during the past decade of the Company's Generx clinical development program. The presentation is available for viewing at http://www.cardiumthx.com/generx.html.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

"The presentation yesterday reviewed new techniques that have been implemented to optimize our international Phase 3 ASPIRE clinical study for the Company's Generx (Ad5FGF-4) DNA-based angiogenic growth factor drug candidate, including: (1) diagnostic identification of patients likely to be more responsive to angiogenic therapy; (2) new balloon catheter-based delivery methods designed to boost adenovector gene delivery and enhance angiogenic growth factor efficiency; and (3) selection of relevant clinical endpoints which may be useful in future clinical studies and help advance the field of therapeutic angiogenesis," stated Christopher J. Reinhard, Cardium's Chairman and CEO.

Generx is an interventional cardiology-focused product candidate that is being developed to offer a one-time, non-surgical option for the treatment of a medical condition termed cardiac microvascular insufficiency (CMI) in patients with myocardial ischemia and symptomatic chronic stable angina pectoris due to coronary artery disease. Patients with CMI have had an insufficient angiogenic response to their current disease state and may benefit from a biological therapy that enhances cardiac perfusion through the facilitation of collateral vessel formation. Currently, patient inclusion in the ASPIRE study requires evidence of stress induced reversible myocardial ischemia as measured by SPECT imaging. The goal of the Company's Generx product candidate is to improve blood flow to the heart muscle by promoting and enhancing cardiac perfusion through the enlargement of pre-existing collateral arterioles (arteriogenesis) and the formation of new capillary vessels (angiogenesis). Various catheter-based imaging diagnostics including fractional flow reserve and washout collaterometry could enhance the clinical adoption of this non-surgical therapeutic angiogenesis approach following initial registration.

Cardium's extensive preclinical and clinical studies have been instrumental in identifying cardiac ischemia as a key facilitator of non-surgical DNA-based angiogenic therapy. Improved adenovector administration methods combine non-surgical, percutaneous balloon catheter-based delivery to transiently induce ischemia together with the use of nitroglycerin to enhance vector uptake. By increasing cell transfection efficiency and reaching both the peri-ischemic regions and pre-existing collaterals in the heart, this modified approach offers the potential to effectively simulate both angiogenesis and arteriogenesis to bring about improved blood flow. Cardium's new delivery techniques are also designed to provide uniform Generx uptake, to reduce response variability and to allow for the potential treatment of patients with a broader range of associated coronary artery disease.

Cardium has modified the primary endpoint of the ASPIRE clinical study from the traditional measure of improvement in treadmill exercise time (ETT) to a more objective efficacy endpoint of reduction in reversible perfusion deficit based on SPECT myocardial perfusion imaging. Similar to mechanical/surgical cardiac revascularization approaches, the goal of Generx treatment is to improve myocardial perfusion (blood flow). SPECT myocardial perfusion imaging can be used to quantitatively evaluate Generx's effectiveness by measuring improved myocardial blood flow under stress, a key prognostic indicator that is associated with the regenerative process of new collateral vessel formation in and around the regions of ischemia. While walking time during ETT has been a traditional efficacy measure of anti-anginal drugs, it is based on a subjective assessment of chest pain (angina pectoris), does not directly measure improvements in cardiac blood flow, and can be affected by other variables. Positive results from the prior Phase 2a clinical study (Grines et al., J Am Coll Cardiol 2003; 42:1339-47) showed that Generx improved myocardial blood flow in the ischemic region of the hearts of patients following a single intracoronary infusion as measured by the objective efficacy endpoint of SPECT imaging. The observed treatment effect for patients receiving Generx was similar in magnitude to that reported in the literature for patients undergoing angioplasty/stent or revascularization procedures with reversible perfusion defects of comparable size at one year following these procedures.

ASPIRE Study

The ASPIRE study is a 100-patient, randomized and controlled multi-center study currently enrolling patients at up to eight leading cardiology centers in the Russian Federation. The ASPIRE study is designed to further evaluate the safety and effectiveness of Cardium's Generx DNA-based angiogenic product candidate, which has already been tested in clinical studies involving 650 patients at more than one hundred medical centers in the U.S., Europe and elsewhere. The efficacy of Generx is being quantitatively assessed using rest and stress SPECT (Single-Photon Emission Computed Tomography) myocardial imaging to measure improvements in microvascular cardiac perfusion following a one-time, non-surgical, catheter-based administration of Generx. The Cedars-Sinai Medical Center Nuclear Cardiology Core Laboratory in Los Angeles, California, is the central core lab for the study and is responsible for the analysis of SPECT myocardial imaging data electronically transmitted from the Russian medical centers participating in the ASPIRE study. The Russian Health Authority has assigned Generx the therapeutic drug trade name of Cardionovo for marketing and sales in Russia.

An independent long-term prospective study published in Circulation (Meier et al, Circ. 2007; 116:975-983) provided key evidence indicating that men and women with more recruitable collateral circulation have a better chance of surviving a heart attack than patients who have less developed collateral circulation. This important study quantitatively evaluated coronary collateral blood flow in 845 patients with coronary artery disease during a 10-year follow-up period and showed that long-term cardiac mortality was approximately 66% lower in patients with a well-developed coronary collateral network (p=0.019). For the first time, this study showed the importance of collateral circulation beyond simply the relief of angina and provided further support of the potential for long term benefits from angiogenic therapy.

About Cardium

See more here:
Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum

Stem Cell Therapy for Stroke
He is a known case of CVA since July 2010, leading to left sided hemiplegia with speech involvement. On MRI Brain, it was seen to be right MCA infarct. He was managed conservatively and has been undergoing regular rehabilitation since then. Neurologically, he is hypertonic and hyperreflexic. On examination: he has left sided paraesthesia (abnormal sensation). He has near normal left lower extremities voluntary control, but poor voluntary control of left hand, but fair control over left (proximal) upper extremities mainly shoulder and elbow. He has near normal cognition and speech. He has affected fine motor control and gross balance while walking. He has hemiplegic gait. Functionally, he is independent in most ADL and mobility. After Stem Cell Therapy 1) Now grasp of left hand has improved. Can hold glass with minimal assistance and drink water. Earlier could not hold glass. 2) Now uses his left hand more in activities -- drinking water. Earlier it was not possible to drink water and use left hand but now he can. 3) Stiffness in left upper limb reduced. 4) Can now sleep on left side also. Earlier would pain a lot. 5) Now he doesn #39;t require help while putting his pant hooks/buttons (but only in certain pants, which are not tight). Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in www ...

By: neurogenbsi

Read this article:
Stem Cell Therapy for Stroke - Video

Stem Cell Therapy for Spinal Cord Injury c5 - c6
He has history of fall in the swimming pool ,leading to fracture and compression of C4 over C5 and Quadriplegia with complete bowel bladder incontinence . He was operated for C5 corpectomy spiral stabilization. He is on regular rehabilitation since then. Neurologically, he is hypertonic hyperreflexic On examination, he has partial sensory recovery till D1, but complete loss below D1 .He has grade 0 muscle power in bilateral lower extremity wrist below, but grade 3++ muscle power in bilateral shoulders. He has no bowel bladder control is on condom catheter for same on ASIA impairment scale he scores #39;A #39; Functionally, he is dependent for all ADL will chair bound for mobility. On FIM he scores 73 After Stem Cell Therapy 1) Trunk balance has improved in sitting and standing. 2) Touch sensation has improved (10%). 3) Now while standing and exercising, can feel stress coming on joint (proprioception). 4) Spasticity, flexor spasms in lower limb increased. 5) Left thumb movement has started. 6) FIM -- no change. 7) Now spasticity grade 2 to 3. 8) Walking in parallel bars better. Can turn and find it easier than before. Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

More:
Stem Cell Therapy for Spinal Cord Injury c5 - c6 - Video

Stem Cell Therapy for Moderate Mental Retardation with Behavioural Issues
She is a known case of Mental Retardation with history of full term normal delivery, but mother had malaria during pregnancy. She had delayed motor milestones but achieved. She had delay mainly in speech. So she was tested and diagnosed to have MR. Gradually, she developed abnormal behavior and hyperactivity. Neurologically, she has near normal tone, reflexes and muscle power. On examination: She is hyperactive. She has poor social interaction and poor social skills. She has poor attention span. She has aggressive behavior. She is unable to read and write, but goes to a special school. She is unable to follow commands and has delayed speech. She needs assistance in all ADL. After Stem Cell Therapy OT assessment: 1) Hyperactivity has reduced by 30-40%. Now she can sit at one place if activity is of interest for 1-2 hours. She has calmed down a lot. 2) Attention and concentration has improved. Now she follows commands or instructions given. Does not need repetitions. 3) Concepts have improved, recognizes objects, matching colours, alphabets, numbers. 4) Speech is clearer and responses are relevant to questions asked. She sometimes still has repetitive speech or speaks sentences not appropriate to the present situations. 5) Aggressive behaviours have decreased. Initially the first month after SCT -- she showed increased aggressiveness towards younger brother. She would beat her brother for no reason. That slowly reduced. Now rarely does it (only when very angry). 6 ...

By: neurogenbsi

See the rest here:
Stem Cell Therapy for Moderate Mental Retardation with Behavioural Issues - Video

Stem Cell Therapy for Cerebral Palsy
She is a known case of CP with history of full term normal delivery, with birth weight approximately 2.4 kg. But gradually as she grew parents noticed she had delayed motor milestones, so she was tested and diagnosed to have CP. Cause for it was suspected to be maternal TORCH infection during pregnancy. She has been on regular rehabilitation and has also had Botox injections twice. Neurologically, she is hypertonic and hyperreflexic. On examination: she has poor voluntary control of bilateral lower extremities, but near normal upper extremities voluntary control. But her grip is slightly poor. She has slurred speech and near normal bowel bladder control. She has fair oromotor control. Functionally, she needs assistance in all ADL and mobility. She is able to walk with AFOs for short distances. On WeeFIM she scores 57. After Stem Cell Therapy OT assessment: 1) Now able to walk with walker. Shifts weights of pelvis. 2) Stamina has increased. Exercise tolerance has increased. 3) Trunk balance has improved. 4) Now stepping is better, now lifts leg while stepping. 5) Standing without holding for about 50 counts. 6) Fear of falling has reduced. 7) Tightness in LL has reduced. 8) Catching ball is better. 9) Back extensor has improved. 10) Can come on bed without support of wall to get a thrust. 11) FIM improved from 60 to 65 secondary to bathing, dressing. 12) Now uses a potty seat over commode, sits independently. Assessment by Speech Therapist: 1) Loudness has improved. 2 ...

By: neurogenbsi

View post:
Stem Cell Therapy for Cerebral Palsy - Video

Stem Cell Therapy for Left Hemiplegia Stroke
He is a case of right MCA infarct with left hemiplegia since 2009. He was treated conservatively and is able to walk independently, but not able to use left upper extremity. Neurologically, he is hypertonic and hyperreflexic on the left side. On examination: he has grade 3 voluntary control in left lower extremity and walks with aid of a stick. He has hemiplegic gait. Left upper limb voluntary control is poor with spaticity grade 3 in shoulder. On Modified Ashworth Scale spasticity on left side is grade 4. He has normal speech and bowel /bladder control. After Stem Cell Therapy 1) Spasticity has reduced in all muscle of left UE and LE. 2) He can raise his left shoulder upto 100° of range which he couldn #39;t do before. 3) Previously, he used to stretch his left hand only in the morning but now he can do the same throughout the day. 4) He can climb stairs without any support. 5) Balance while standing, walking and stair climbing has improved. 6) Now he can maintain tandem stance for 20 sec without losing balance. 7) He can do marching with leg in standing which he couldn #39;t do before. 8) VC grading : elbow 3 knee 4 Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

Excerpt from:
Stem Cell Therapy for Left Hemiplegia Stroke - Video

A new study published this month in the journal Human Gene Therapy has shown that a modified protein from the HIV virus itself could someday be used to prevent AIDS.

This is like fighting fire with fire, said David Harrich, co-author of the study and an associate professor at the Queensland Institute of Medical Researchs (QIMR) Molecular Virology Laboratory. If this research continues down its strong path, and bear in mind there are a many hurdles to clear, were looking at a cure for AIDS.

Harrich runs the only research laboratory in Queensland that works with the HIV virus. The protein he and his colleagues discovered, named Nullbasic, was formed by mutating an existing HIV protein over many generations. The researchers are confident enough in their findings that animal trials are set to begin this year.

Patients infected with the HIV virus currently take large doses of expensive drugs to subdue the virus. Nullbasic treatments wouldnt eliminate HIV from patients bodies but, according to Harrich, it could significantly reduce the cost of treatment for HIV.

I have never seen anything like it. The modified protein works every time, said Harrich. You would still be infected with HIV, its not a cure for the virus. But the virus would stay latent, it wouldnt wake up, so it wouldnt develop into AIDS. With a treatment like this, you would maintain a healthy immune system.

Harrich has been studying HIV since the early 1980s, when the very first cases of AIDS began to be diagnosed. He began as a research assistant at the University of California, Los Angeles (UCLA).

Ive come close to giving up in the past, said Harrich. But today Im so encouraged. I feel very fortunate because not a lot of scientists are able to stay in the same game long enough to see these sorts of developments.

The video below was released by QIMR. It features Harrich discussing his teams Nullbasic findings.

Go here to see the original:
Potential AIDS Cure Could Make HIV Dormant

Washington, January 27 (ANI): An Indian origin scientist and his team analyzed the genomes of 14 family members who were affected by malignant melanoma and found an identical mutation in the gene for telomerase, an enzyme often called 'immortality enzyme', in all persons studied.

Telomerase protects the ends of chromosomes from being lost in the process of cell division and, thus, prevents that the cell ages and dies. The inherited gene mutation leads to the formation of a binding site for protein factors in the controlling region of the telomerase gene, causing it to become overactive. As a result, mutated cells overproduce telomerase and hence become virtually immortal.

This spectacular finding of the family analysis prompted the scientists to also look for mutated telomerase genes in non-inherited (sporadic) melanoma, which is much more common than the familial variant.

In most of the tissue samples of melanomas of all stages they found alterations in the telomerase gene switch, which the researchers clearly identified as typical consequences of sun exposure. Even though these mutations were not identical to those found in the melanoma family, they had the same effect: overactive telomerase.

"We don't believe that the telomerase gene in melanoma is mutated by pure chance, but that it is a so-called driver mutation that drives carcinogenesis," said Prof. Dr. Rajiv Kumar of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) who conducted the study together with Prof. Dr. Dirk Schadendorf from Essen University Hospital.

This is also confirmed by the surprising incidence of this alteration: The telomerase gene is the most frequently mutated gene in melanoma.

"This is something we hadn't expected, because malignant melanoma has been genetically analyzed thoroughly. But this mutation always seems to have been overlooked," said Kumar.

Kumar, Dirk Schadendorf and their teams are hoping that the alterations in the telomerase gene may be a starting point for developing novel treatment methods for malignant melanoma. (ANI)

See the original post here:
Familial gene mutation immortalizes deadly skin cancer

My Father, My Hero- (a painful 2min puke session)
My 70 yr old father just about throws up his internal organs for a incredibly painful two minutes straight. After drinking a fifth of SoCo, i convinced him that smoking a blunt with me would be the proper thing to do. After all, hanging out with the old man is a rare thing these days- so I thought, what the hell , right ? Having last smoked in 1969 , this video shows a direct result of the wonders of modern pharmaceutical science. A "crash course" in genetic engineering, if you will, and in manipulation of the genetic makeup of the cannabis seed. So, in closing, this is what happens when you introduce your dad to my friend Jack Herer. I encourage others to do the same.

By: cannybiss

Link:
My Father, My Hero- (a painful 2min puke session) - Video

Genes1
The latest in genetic engineering

By: 99DarkHorses

Original post:
Genes1 - Video